目的 探讨胃复春片联合枸橼酸莫沙必利片治疗慢性萎缩性胃炎的临床疗效。方法 选取2015年7月-2017年7月在上海市浦东新区人民医院进行治疗的慢性萎缩性胃炎患者212例为研究对象，入选者根据用药的差别分为对照组和治疗组，每组各106例。对照组口服枸橼酸莫沙必利片，5 mg/次，3次/d。治疗组在对照组治疗基础上口服胃复春片，4片/次，3次/d。两组均连续治疗2周。观察两组的临床疗效，比较两组的临床症状评分和血清学指标。结果 治疗后，对照组和治疗组的总有效率分别为83.96%、98.11%，两组比较差异有统计学意义（P<0.05）。治疗后，两组胃脘疼痛、胃中嘈杂、嗳气泛酸和口苦口干评分均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清白细胞介素-1β（IL-1β）、人可溶性白介素-2受体（sIL-2R）、胃泌素（GAS）、胃动素（MTL）水平明显降低，胃泌素-17（G-17）水平明显增高（P<0.05），同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 胃复春片联合枸橼酸莫沙必利片治疗慢性萎缩性胃炎具有较好的临床疗效，可改善临床症状，降低机体炎症反应，调节胃肠激素水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Weifuchun Tablets combined with Mosapride Citrate Tablets in treatment of chronic atrophic gastritis. Methods Patients (212 cases) with c chronic atrophic gastritis in Shanghai Pudong New Area People's Hospital from July 2015 to July 2017 were enrolled in this study. According to the difference treatment plan, patients were divided into control and treatment groups, and each group had 106 cases. Patients in the control group were po administered with Mosapride Citrate Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Weifuchun Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and clinical symptom scores and serological indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.96% and 98.11%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of epigastric pain, noisy stomach, eructation pantothenic acid, bitter taste, and dry throat in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of serum IL-1β, sIL-2R, GAS, and MTL in two groups were significantly decreased, but the levels of G-17 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Weifuchun Tablets combined with Mosapride Citrate Tablets has clinical curative effect in treatment of chronic atrophic gastritis, can improve clinical symptoms, decrease the inflammatory reaction, and regulate the level of gastrointestinal hormones, which has a certain clinical application value.